


Claims.

1. An (indol-3-yl)-heterocycle derivative having the general Formula I



Formula I

5 wherein

A represents a 5-membered aromatic heterocyclic ring, wherein X₁, X₂ and X₃ are independently selected from N, O, S and CR;

R is H or (C₁₋₄)alkyl; or

R, when present in X₂ or X₃, may form together with R₃ a 5-8 membered ring;

10 R₁ is a 5-8 membered saturated carbocyclic ring, optionally containing a heteroatom selected from O and S;

R₂ is H, CH₃ or CH₂-CH₃; or

15 R₂ is joined together with R₇ to form a 6-membered ring, optionally containing a heteroatom selected from O and S, and which heteroatom is bonded to the 7-position of the indole ring;

R₃ and R₄ are independently H, (C₁₋₆)alkyl or (C₃₋₇)cycloalkyl, the alkyl groups being optionally substituted with OH, (C₁₋₄)alkyloxy, (C₁₋₄)alkylthio, (C₁₋₄)alkylsulfonyl, CN or halogen; or

20 R₃ together with R₄ and the N to which they are bonded form a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy, (C₁₋₄)alkyloxy-(C₁₋₄)alkyl, or halogen; or

25 R₃ together with R₅ forms a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy, (C₁₋₄)alkyloxy-(C₁₋₄)alkyl, or halogen; or

R₃ together with R, when present in X₂ or X₃, forms a 5-8 membered ring;

R₅ is H or (C₁₋₄)alkyl; or

- R₅ together with R₃ forms a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy, (C₁₋₄)alkoxy- (C₁₋₄)alkyl, or halogen;
 R₅' is H or (C₁₋₄)alkyl;
- 5 R₆ represents 1-3 substituents independently selected from H, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy, CN and halogen;
 R₇ is H, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy, CN or halogen; or
 R₇ is joined together with R₂ to form a 6-membered ring, optionally containing a further heteroatom selected from O and S, and which heteroatom is bonded to the
 10 7-position of the indole ring; or a pharmaceutically acceptable salt thereof.
2. The (indol-3-yl)-heterocycle derivative of claim 1, wherein R₂ is H or is joined together with R₇ to form a 6-membered ring, optionally containing a heteroatom selected from O and S, and which atom is bonded to the 7-position of the indole
 15 ring.
3. The (indol-3-yl)-heterocycle derivative of claim 1 or 2, wherein R, R₅, R₅' and R₆ are H.
- 20 4. The (indol-3-yl)-heterocycle derivative of any one of claims 1-3, wherein R₁ is cyclohexyl or tetrahydropyranyl.
5. The (indol-3-yl)-heterocycle derivative of any one of claims 1-4 where the heterocycle A is 1,2,4-oxadiazole (X₁ is N, X₂ is O, X₃ is N), 1,2,4-thiadiazole (X₁ is
 25 N, X₂ is S, X₃ is N) or thiazole (X₁ is S, X₂ is CR, X₃ is N).
6. The (indol-3-yl)-heterocycle derivative of claim 1 which is selected from:
- 7-Chloro-3-(5-[[N-ethyl-N-(2-methoxyethyl)amino]methyl]-[1,2,4]-thiadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
 - 30 - 7-Chloro-3-(5-[(pyrrolidin-1-yl)methyl]-[1,2,4]-thiadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
 - 7-Chloro-3-(5-[[N-ethyl-N-(2-hydroxyethyl)amino]methyl]-[1,2,4]-thiadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
 - 7-Chloro-3-(4-[[N-(2-hydroxyethyl)-N-isopropylamino]methyl]-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
 - 35 - 7-Chloro-3-(4-[[N-ethyl-N-(2-hydroxyethyl)amino]methyl]-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;

- 7-Chloro-3-(4-[[N-(2-methoxyethyl)-N-methylamino]methyl]-[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
 - 7-Chloro-3-(5-[(2,2-dimethyl-pyrolidin-1-yl)methyl]-[1,2,4]oxadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 5 or a pharmaceutically acceptable salt thereof.
7. The (indol-3-yl)-heterocycle derivative of any one of claims 1-6 for use in therapy.
8. A pharmaceutical composition comprising an (indol-3-yl)-heterocycle derivative of
- 10 any one of claims 1-6 in admixture with pharmaceutically acceptable auxiliaries.
9. Use of an (indol-3-yl)heterocycle derivative of Formula I as defined in claim 1, in the preparation of a medicament for the treatment of pain.
- 15 10. A method of treatment of pain such as peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis, by administering to a patient in need thereof a therapeutically effective amount of an (indol-3-yl)-heterocycle derivative of any one of claims 1-6.